Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Work In Process (2021 - 2024)

Apellis Pharmaceuticals has reported Work In Process over the past 4 years, most recently at $106.2 million for Q1 2024.

  • Quarterly results put Work In Process at $106.2 million for Q1 2024, up 119.02% from a year ago — trailing twelve months through Mar 2024 was $106.2 million (up 119.02% YoY), and the annual figure for FY2023 was $82.9 million, up 53.28%.
  • Work In Process for Q1 2024 was $106.2 million at Apellis Pharmaceuticals, up from $82.9 million in the prior quarter.
  • Over the last five years, Work In Process for APLS hit a ceiling of $106.2 million in Q1 2024 and a floor of $10.1 million in Q4 2021.
  • Median Work In Process over the past 4 years was $48.4 million (2023), compared with a mean of $48.1 million.
  • Biggest five-year swings in Work In Process: surged 437.89% in 2022 and later surged 53.28% in 2023.
  • Apellis Pharmaceuticals' Work In Process stood at $10.1 million in 2021, then surged by 437.89% to $54.1 million in 2022, then surged by 53.28% to $82.9 million in 2023, then rose by 28.02% to $106.2 million in 2024.
  • The last three reported values for Work In Process were $106.2 million (Q1 2024), $82.9 million (Q4 2023), and $52.1 million (Q3 2023) per Business Quant data.